Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced tha...
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that a poster supporting the potential of SZN-413 for the...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Surrozen press release (NASDAQ:SRZN): FY GAAP EPS of -$2.21 beats by $0.09. Cash Position: Cash, cash equivalents and marketable securities were $123.5 million as of December 31, 2021, compared to $135.4 million as of September 30, 2021. For further details see: Surrozen GAAP EPS of -$2...
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported fi...
Gainers: Sunshine Biopharma (NASDAQ:SBFM) +183%. Bumble (NASDAQ:BMBL) +42%. Bone Biologics (OTCPK:BBLG) +36%. Cano Health (NYSE:CANO) +35%. CPS Technologies (NASDAQ:CPSH) +29%. AST SpaceMobile (NASDAQ:ASTS) +31%. Hudson Technologies (NASDAQ:HDSN) +30%. FIGS (NYSE:FIGS) +30%. Fluent (NASDAQ:FL...
Gainers: HOOKIPA Pharma (NASDAQ:HOOK) +46%. Kinnate Biopharma (NASDAQ:KNTE) +9%. Corcept Therapeutics (NASDAQ:CORT) +7%. Alkermes (NASDAQ:ALKS) +5%. Celularity (NASDAQ:CELU) +3%. Losers: Masimo (NASDAQ:MASI) -36%. Baudax Bio (NASDAQ:BXRX) -20%. ...
-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022 -Acceleration of preclinical programs includes nomination of lead candidate SZN-413 for retinopathies and compelling preclinical data highlighting the potential for lacrimal gland...
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present ...
The following slide deck was published by Surrozen, Inc. in conjunction with this event. For further details see: Surrozen (SRZN) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 109.0% to $0.3668 on volume of 102,385,159 shares Maxeon Solar Technologies Ltd. (MAXN) rose 4.3% to $0.181 on volume of 66,422,365 shares NVIDIA Corporation (NVDA) fell 1.3% to $126.58 on volume...
Targeted protein degradation (TPD * ) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are unique TPD technologies Results demonstrated that the two new ASGR-targeted SWEETS bispecific a...
SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Phase 1...